The 8th Annual Microbiome Connect: Europe 2022 is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers. As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications. Furthermore, separate tracks will be committed to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skin care applications. Meet Daniel Endler in Amsterdam!